Biotech IPOs Grow Larger in Q1 2026 Despite Slow Pace, Raising $1.7 Billion
核心洞察
Biopharma companies raised a combined $1.7 billion in IPOs during the first quarter of 2026, the highest quarterly total since 2021.
The median biotech IPO raised $287.5 million, more than double the median seen in Q1 2025, though the number of offerings remained similar to recent years.
Nearly all companies that successfully priced an IPO had drugs in mid- or late-stage clinical testing, while preclinical companies have been shut out since 2024.
Biotechnology initial public offerings continued to price at a slow pace in the first three months of 2026, but the amount raised in initial share sales has soared compared to previous years. Biopharma companies collectively banked $1.7 billion in IPOs in the first quarter, the most of any quarter since 2021, according to BioPharma Dive data. Three of those companies raised more than $300 million, a benchmark rarely seen since the sector's peak in 2021.
So far in 2026, biotechs have raised a median of $287.5 million, more than double what was seen during January through March of last year and the highest quarterly median since 2021. Yet the number of total offerings remained largely similar to what was observed between 2022 and 2025 — years that represented departures from pre-pandemic norms.
A Cautious Recovery Amid Macroeconomic Headwinds
Biotech investors entered 2026 optimistic that IPOs were poised for a long-awaited rebound. But the numbers have not spiked as hoped, said Jonathan Norris, a managing director at HSBC Innovation Banking (搜索), which tracks financing and deal trends for young healthcare companies.
Two culprits may be "macro economic factors and revolving door at [the] FDA," Norris said. Renaissance Capital, a prominent IPO research firm, echoed similar sentiments in a quarterly review, noting how "surging volatility," including the war in the Middle East, "grounded the IPO party before it took off."
The recovery remains fragile. After the extraordinary 2021 boom — when more than 100 biotech companies went public and raised nearly $16 billion, fueled in part by the COVID-19 pandemic — the door largely shut. In 2025, only 11 drugmakers priced initial public offerings. Policy uncertainty has compounded the slowdown, with a sector dependent on long investment horizons absorbing uncertainty around Medicare drug pricing caps, regulatory skepticism of industry consolidation, and broader questions about the future return on biomedical innovation.
Later-Stage Assets Dominate the IPO Pipeline
The biotechs that have managed to price an offering so far in 2026 continue to fit the mold of the companies that saw the most success in 2025. All but one had drugs in mid- or late-stage clinical testing. They also all previously raised large amounts of venture funding and were developing drugs in hot areas of research such as autoimmune conditions or cancer.
Offerings remain largely shut to companies not meeting this criteria. BioPharma Dive data show that no preclinical companies have gone public since 2024. But some investors believe that could change in the months ahead.
"As the market continues to perform, we should see more companies pursuing the IPO route, including smaller offerings and potentially earlier-stage or higher-risk opportunities," said Antoine Papiernik, managing partner and chairman of venture capital firm Sofinnova Partners (搜索).
Should the window open for higher-risk opportunities, companies that have had a harder time going public of late — such as cell and gene therapy developers — could be beneficiaries. The last one to go public, Artiva Biotherapeutics, did so in July 2024.
Platform Companies Test Investor Appetite
Companies with broad drugmaking platforms that typically take time to mature could benefit from a widening window, too. Biotechs built around one or even a few drug prospects have made up the bulk of recent offerings, and the year's best-performing newly public company, Veradermics (搜索), is primarily focused on a single therapy for hair loss.
The investor demand for those offerings encouraged some platform-centric counterparts, such as Eikon Therapeutics (搜索) and Generate Biomedicines (搜索), to test the public markets as well. Both priced lucrative IPOs, but at lower valuations than they had once commanded as private companies. They also both currently trade below their offering price.
"Product-focused companies built around clinically grounded programs are forming the backbone of the window, while larger platform-oriented issuers are testing how far investor appetite can extend beyond near-term validation," Ben Zercher, a senior biotech and pharma analyst at PitchBook, wrote in a February statement.
The Looming Shadow of Mega Tech IPOs
A risk to this delicate reopening is that it could be overwhelmed by a very different kind of IPO. SpaceX, OpenAI, and Anthropic are being discussed as the defining public-market events of 2026. SpaceX has a reported plan to raise $75 billion at a $1.75 trillion valuation. OpenAI has reportedly prepared for an IPO that could value the company at up to $1 trillion. Anthropic has confidentially submitted a draft S-1 and recently announced a $65 billion funding round at a $965 billion post-money valuation.
In theory, public markets are deep enough to fund many sectors simultaneously. In practice, IPO windows depend on risk appetite, liquidity, portfolio allocation, and narrative momentum. A trillion-dollar technology debut does not merely compete for dollars; it competes for attention. Growth funds that might otherwise consider investing in a Phase 2 immunology company, an oncology platform, or a rare-disease developer may instead reserve capital for the next AI or aerospace infrastructure giant.
The result may not be a closed biotech window, but a narrower one — meaning fewer issuers, lower valuations, smaller proceeds, more dilutive offerings, and longer waits for companies that are ready to go public but cannot command attention. Some companies will stay private longer and raise more expensive venture rounds. Others may cut programs, delay trials, or seek acquisition before their science has had time to mature. For biotech, delayed capital formation can become delayed clinical development.
Investors have told BioPharma Dive that they have increasingly pushed their portfolio companies to consider the public markets. Norris suggests that 20 offerings would be considered a "good year" for the sector, as it would represent an improvement over 2025's paltry total of 11 and more in line with what was seen in the few years prior.
There is also a broader policy dimension. Policymakers frequently emphasize U.S. leadership in biotechnology, domestic innovation, biomedical preparedness, and the need to convert innovative medical discoveries into treatments. Those goals require more than NIH funding, FDA efficiency, or the avoidance of price caps — they also require functioning capital markets. If the public market becomes overwhelmingly organized around a handful of spectacular technology narratives, it becomes less useful for financing diversified innovation.